This activity will provide pharmacists, residents, and pharmacy technicians with information in order to help determine how to provide safe and efficacious therapy options for the patients with high risk or refractory/relapsed neuroblastoma. The Children’s Oncology Group (COG) trials have been studying and using dinutuximab as antibody therapy for treatment of high risk and refractory/relapsed neuroblastoma. Recently, trials have demonstrated that adding on antibody therapy to standard treatment can help with prognosis and survival of neuroblastoma, which has lead to the discovery of dinutuximab. However, this is a costly intravenous therapy which requires long administration infusions and requires inpatient admissions. With the recently FDA approved agent naxitamab with indications for high risk and refractory/relapsed neuroblastoma, and newer primary literature emerging, naxitamab has the potential to be more cost effective and allow outpatient administration of the infusion for much shorter times. This presentation will review primary literature behind the use of antibody therapy, and especially for naxitamab, for high risk and relapsed/refractory neuroblastoma and help identify its place in practice.